Acesulfame Potassium

What It Is

Acesulfame potassium, usually shortened to Ace-K, is a high-intensity sweetener about 200 times sweeter than table sugar according to FDA. In the EU it is E 950. The food additive is the potassium salt, not the free acid that shares most of its name.

The body does not metabolise it. JECFA’s absorption and distribution data show it passes through largely unchanged. So Ace-K is calorie-free in the plain sense, not just negligible at the amounts used.

It is rarely used alone. FDA notes it “is often combined with other sweeteners”, most often aspartame, which has the same sweetness. The reason is heat.

Heat Stability, and Why It Is Blended

FDA: Ace-K “is heat stable, meaning it stays sweet even when used at hot temperatures during baking, making it suitable as a sugar substitute in baked goods.” Regulators do not disagree about this, as they do for sucralose. It is the opposite of aspartame, which loses its sweetness when heated. In a blend, aspartame supplies the cleaner taste and Ace-K supplies the heat tolerance and shelf life. Blending also lets a formulator use less of each.

Regulatory Status

In the US, Ace-K is an approved food additive, codified at 21 CFR 172.800, in the same Part as aspartame and sucralose. It went through the full petition process; it is not a GRAS notification. FDA approved it for specific food and beverage categories in 1988, and as a general-purpose sweetener and flavour enhancer, except in meat and poultry, in 2003. FDA reviewed more than 90 toxicity studies.

The 1988 approval was contested. The Center for Science in the Public Interest objected that the long-term rat cancer study was inadequate. FDA had a consulting pathologist re-examine the tissue slides and concluded “there is no association between the occurrence of neoplasms and treatment with acesulfame potassium.”

In the EU, Ace-K is authorised as E 950. EFSA’s most recent re-evaluation was published on 30 April 2025.

The ADI: Three Regulators, One Number

For aspartame and sucralose, regulators set different acceptable daily intakes. For Ace-K, all three now agree on 15 mg/kg of body weight per day. They did not always agree; two of them moved to meet the third:

• FDA set 15 at its first approval in 1988. It took the highest dose in a long-term rat study (3% of the diet) and applied “a 100-fold safety factor”.
• JECFA first set 9, based on a two-year dog study. At its 37th meeting in 1990 it raised the figure to 15, once the rat study’s higher no-effect level of 1,500 mg/kg bw/day was available.
• The EU also set 9 at first, and EFSA kept that figure until its 2025 re-evaluation moved it to 15, based on the same rat study. For 35 years the EU was the outlier.

Who Comes Closest to the Limit

In EFSA’s 2025 modelling, the 95th percentile of intake ranged from 0.2 mg/kg bw/day in children aged 3 to 9 and in adults to 15.7 mg/kg bw/day in toddlers. That toddler figure is above the ADI of 15. EFSA’s overall conclusion was still that “current dietary exposure estimates do not indicate a safety concern for acesulfame K”, a conclusion that rests on the uncertainty margins in its method, not on toddlers staying under the line. We state the figure as EFSA gave it; 15.7 is not “approaching” 15. Stevia has a similar finding for toddlers.

EFSA’s September 2026 opinion on the aspartame-acesulfame salt (E 962) made no new estimate for Ace-K. It relied on the 2025 assessment as “sufficiently recent”.

Breakdown Products and an Open Impurity Question

Ace-K can break down into acetoacetamide and acetoacetamide-N-sulfonic acid. JECFA reviewed both in 1990 and found them low in toxicity and not mutagenic. EFSA concluded in 2025 that “no safety concerns arise for genotoxicity of acesulfame K (E 950) and its degradation products.”

One possible impurity of the manufactured additive is a separate matter. For 5-chloro-acesulfame, EFSA stated that “a concern for genotoxicity was identified”. The concern rests on computer modelling (QSAR), because no experimental toxicity data exist for it. If acesulfame K contained 2 mg/kg of it, intake would exceed the threshold EFSA uses for potentially genotoxic compounds, so EFSA recommended a maximum limit of 0.1 mg/kg in the EU specifications, or new genotoxicity data instead. In 2026 EFSA said the same uncertainty applies to the aspartame-acesulfame salt, and recommended making the salt only from Ace-K that meets the revised specifications. As of that opinion, the revisions had not been formally written into EU law. This is an open question about an impurity, not a finding about Ace-K itself.

The Cancer Evidence

Two studies point in different directions, and both are stated here with their funding.

For an association: the French NutriNet-Santé cohort (Debras et al., 2022) followed 102,865 adults for a median of 7.7 years. Higher Ace-K intake was associated with higher overall cancer risk, a hazard ratio of 1.13 (95% CI 1.01–1.26), close to aspartame’s 1.15 in the same cohort. The authors set out their own limits: participants were more educated and health-conscious than the general population, so “caution must be taken in extrapolating the results”, and “causal links cannot be established by this unique study; in particular, residual confounding bias cannot be entirely ruled out.” The study was publicly funded, by French public health and research bodies, the European Research Council and the French National Cancer Institute. One author co-founded the nonprofit Open Food Facts database, declared as a non-financial interest.

Against a consistent signal: a 2025 systematic review of 90 epidemiological studies (Boon et al.) found “no consistent associations between any NSS or NSSs in aggregate and any cancer overall, and no evidence for dose-response”. It rated NutriNet-Santé among the four better cohorts for measuring exposure, but called its “sparse 24-h recall data” still “not ideal”. One of that review’s authors is affiliated with the American Beverage Association.

Neither side’s funding disqualifies its findings. What would settle the question: the same association in another large cohort with better exposure data, or a mechanism by which a compound that passes through the body unmetabolised could cause it.

Calories, Carbohydrate and Blood Glucose

Pure Ace-K has no calories and no carbohydrate, and it subtracts in full from net carbs. Because it is almost always blended, the product’s Total Carbohydrate depends on whatever else is in it, not on the Ace-K. Our record has no dedicated glucose or insulin trial for Ace-K, and it shows no blood-sugar benefit or harm from it. The open question above is about long-term cancer risk, not blood glucose.

Comparison Note

Against aspartame: the same sweetness and the same open cancer-cohort question, but Ace-K survives heat and has no calories at all. Against sucralose: both are heat stable and both are full food additives, but regulators agree on Ace-K’s ADI and disagree on sucralose’s. Against saccharin: neither is used by the body for energy, and each has an EU question about impurities from manufacturing.

Regulators agree on Ace-K’s approval and its limit. The open questions are an impurity limit the EU has not yet adopted, and a cohort finding that has not been replicated.